Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
09:00-09:15 | 09:00-09:15 |
Optimal Management Strategy for T2DM Patients with ASCVD |
Yihong Sun | China-Japan Friendship Hospital |
09:15-09:22 | 09:15-09:22 |
Discussion |
||
09:22-09:37 | 09:22-09:37 |
Does GLP-1RA Have Class Effect in ASCVD Prevention? |
Jiangli Han | Peking University Third Hospital |
09:37-09:44 | 09:37-09:44 |
Discussion |
||
09:44-09:59 | 09:44-09:59 |
Comparison between DAPA-HF and EMPEROR-HF Trial |
baoxia chen | Peking University Third Hospital |
09:59-10:06 | 09:59-10:06 |
Discussion |
||
10:06-10:21 | 10:06-10:21 |
Insights from CREDANCE Trial and DAPA-CKD Trial |
Xiaoyan Xing | China-Japan Friendship Hospital |
10:21-10:30 | 10:21-10:30 |
Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
11:00-11:15 | 11:00-11:15 |
LDL-C, Non-HDL-C, ApoB: Which Is the Best Target of Lipid-lowering Treatment? |
Daoquan Peng | The Second Xiangya Hospital of Central South University |
11:15-11:22 | 11:15-11:22 |
Discussion |
||
11:22-11:37 | 11:22-11:37 |
Can Non-Fasting Blood Lipid Replace Fasting Blood Lipid for Risk Assessment? |
Ling Liu | The Second Xiangya Hospital of Central South University |
11:37-11:44 | 11:37-11:44 |
Discussion |
||
11:44-11:59 | 11:44-11:59 |
Clinical Value of LP (a) in ASCVD Risk Prediction |
Yong-Ming He | The First Affiliated Hospital of Soochow University |
11:59-12:06 | 11:59-12:06 |
Discussion |
||
12:06-12:21 | 12:06-12:21 |
Current situation and Prospect of Metabolic Cardiovascular Disease |
Yida Tang | Peking University Third Hospital |
12:21-12:30 | 12:21-12:30 |
Disscussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
12:30-12:55 | 12:30-12:55 |
Interpretation of Expert Consensus on Coronary Microcirculation |
Xiaochang Ma | |
12:55-13:10 | 12:55-13:10 |
Diagnosis and Treatment Strategies for Coronary Microvascular Disease |
Chun Liang | Shanghai Changzheng Hospital |
13:20-13:30 | 13:20-13:30 |
Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
14:00-14:15 | 14:00-14:15 |
How to Control Multi Risk Factors of Diabetes, Dyslipidemia and Hypertension to Achieve Clinical Cardiovascular Benefits? |
Yong Li | Huashan Hospital Fudan University |
14:15-14:30 | 14:15-14:30 |
Mechanisms of Sympathetic Activation in Metabolic Syndrome and Intervention Strategy |
Zhongwei Shi | Ruijin Hospital, Shanghai Jiaotong University School of Medicine |
14:30-14:45 | 14:30-14:45 |
Domestic Lipid Regulating Medicine in ASCVD Primary Prevention |
Ping Ye | The Second Medical Center of PLA General Hospital |
14:45-15:00 | 14:45-15:00 |
New Pattern of Heart Failure Treatment——Interpretation of DAPA-HF |
Xinli Li | Jiangsu Province Hospital ( The First Affiliated Hospital with Nanjing Medical University) |
15:00-15:30 | 15:00-15:30 |
Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
16:00-16:15 | 16:00-16:15 |
Management of CVD and DM: Clinical Cases |
Xiaowei Yan | Peking Union Medical College Hospital |
16:15-16:30 | 16:15-16:30 |
Current Epidemic and Management Status of CVD and DM |
Jing Liu | Beijing Anzhen Hospital, Capital Medical University |
16:30-16:45 | 16:30-16:45 |
Review of Guidelines and Evidences on CVD and DM Management |
Yong Li | Huashan Hospital Fudan University |
16:45-17:00 | 16:45-17:00 |
The Management of CVD and DM-Novel Antidiabetic Drugs |
Daoquan Peng | The Second Xiangya Hospital of Central South University |
17:00-17:30 | 17:00-17:30 |
Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
17:30-17:45 | 17:30-17:45 |
Should Metformin Be Used as the First-line Drug for Primary Prevention of ASCVD in Diabetes Mellitus? |
Yifang Guo | Hebei General Hospital |
17:45-18:00 | 17:45-18:00 |
Research Progress of Cholesterol Metabolism |
Xubo Shi | Beijing Tongren Hospital, Capital Medical University, |
18:00-18:15 | 18:00-18:15 |
Lipid Regulation Strategy for Chinese Diabetic Patients |
Dan ZHU | |
18:15-18:30 | 18:15-18:30 |
Interpretation of 2020 CSC Chinese Expert Consensus on Lipid Management of very High-risk Atherosclerotic Cardiovascular Disease Patients |
Ming Cui | Peking University Third Hospital |
18:30-18:45 | 18:30-18:45 |
Reducing the Residual Risk of Cardiovascular Events: the Role of Triglycerides |
li sheng | |
18:45-19:00 | 18:45-19:00 |
Polyunsaturated Fatty Acids and ASCVD: Mechanisms other than Triglycerides? |
Ling Liu | The Second Xiangya Hospital of Central South University |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
19:00-19:15 | 19:00-19:15 |
Residual cardiovascular risk and residual risk management |
Dong Zhao | Beijing Anzhen Hospital |
19:15-19:30 | 19:15-19:30 |
Overview of Asia Lipid Management: Clinical Practice and New Development |
Kwang Kon Koh | Gachon University Gil Medical School |
19:30-19:45 | 19:30-19:45 |
Overview of Blood Lipid Management in Hong Kong |
Hung-Fat Tse | University of Hong Kong |
19:45-20:00 | 19:45-20:00 |
Explore the Mechanism of IPE |
Yihong Sun | China-Japan Friendship Hospital |
20:00-20:15 | 20:00-20:15 |
From REDUCE-IT to EVAPORATE to Analyze the Evidence Chain of IPE Cardiovascular Protection |
Deepak L. Bhatt | Brigham And Women's Hospital |
20:15-21:00 | 20:15-21:00 |
Discussion |